๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

4,760 results for โ€œPharmโ€ Clear

  1. RO7496998

    Atea Pharmaceuticals

    COVID-19

    phase 3 small molecule terminated

    1 trial
  2. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial
  3. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial
  4. Ramosetron

    Astellas Pharma Inc

    Vomiting

    phase 3 small molecule completed

    1 trial
  5. Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial
  6. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    1 trial
  7. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial
  8. Ranibizumab 0.5 mg

    Novartis Pharmaceuticals

    Central Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial
  9. Rapastinel

    Allergan Pharmaceuticals International Limited

    Depressive Disorder, Major

    phase 3 small molecule terminated

    1 trial
  10. Rasagiline

    Teva Pharma GmbH

    Progressive Supranuclear Palsy

    phase 3 small molecule terminated

    1 trial
  11. Recombinant Anti-IL-1ฮฒ Humanized Monoclonal Antibody Injection 200 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Gout

    phase 3 small molecule active

    2 trials
  12. Recombinant Human VEGF Receptor-Fc Fusion Protein

    Biotech Pharmaceutical Co.,

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial
  13. Recombinant SARS-CoV-2 fusion protein vaccine (V-01)

    Livzon Pharmaceutical Group

    COVID-19 Pandemic

    phase 3 mab active

    1 trial
  14. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial
  15. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria

    phase 3 small molecule active

    1 trial
  16. Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial
  17. Reslizumab

    Teva Pharma GmbH

    Eosinophilic Asthma

    phase 3 small molecule completed

    5 trials
  18. Reslizumab

    Teva Pharma GmbH

    Severe Persistent Asthma

    phase 3 mab completed

    1 trial
  19. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule active

    1 trial
  20. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial
  21. Revatio 0.8 mg/ml solution for injection

    Pari Pharma GmbH

    Hypoxic ischemic encephalopathy

    phase 3 small molecule active

    1 trial
  22. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 3 small molecule completed

    2 trials
  23. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial
  24. Revlimid 20 mg hard capsules, Dexamethason 4 mg JENAPHARMยฎ, VELCADE 3.5 mg powder for solution for injection, DEXAMETHASONE , Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 10 mg hard capsules, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources